(CERS) Cerus - Ratings and Ratios
Blood, Sterilization, Medical, Equipment
CERS EPS (Earnings per Share)
CERS Revenue
Description: CERS Cerus
Cerus Corporation is a biomedical products company that develops and commercializes the INTERCEPT Blood System, a proprietary technology designed to enhance blood safety by reducing blood-borne pathogens in donated blood components. The companys products include INTERCEPT Blood Systems for platelets, plasma, and red blood cells, which are sold through a direct sales force and distributors globally.
From a business perspective, Cerus Corporation has a significant presence in the healthcare industry, specifically in the health care supplies sub-industry. The companys focus on blood safety and pathogen reduction positions it in a niche market with potential for growth, driven by increasing demand for safe blood products. Key performance indicators (KPIs) to watch include revenue growth, gross margin, and sales penetration in key markets such as the United States and Europe.
Analyzing Cerus Corporations financials, the companys market capitalization stands at approximately $260 million, indicating a relatively small-cap stock. The absence of a price-to-earnings (P/E) ratio suggests that the company is not yet profitable, which is consistent with the negative return on equity (RoE) of -35.31%. Other important KPIs to monitor include cash burn rate, research and development (R&D) expenses as a percentage of revenue, and the companys cash runway. These metrics will provide insights into Cerus Corporations ability to execute its business plan and achieve profitability.
To evaluate the companys stock performance, we can look at metrics such as trading volume, short interest, and institutional ownership. These indicators can provide insights into market sentiment and potential price movements. Additionally, monitoring news and announcements from the company, such as product approvals, partnerships, or clinical trial results, can help identify potential catalysts for stock price changes.
CERS Stock Overview
| Market Cap in USD | 226m |
| Sub-Industry | Health Care Supplies |
| IPO / Inception | 1997-01-30 |
CERS Stock Ratings
| Growth Rating | -85.4% |
| Fundamental | 39.3% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -49.5% |
| Analyst Rating | 4.60 of 5 |
CERS Dividends
Currently no dividends paidCERS Growth Ratios
| Growth Correlation 3m | -68.2% |
| Growth Correlation 12m | -82% |
| Growth Correlation 5y | -93.2% |
| CAGR 5y | -31.88% |
| CAGR/Max DD 3y | -0.44 |
| CAGR/Mean DD 3y | -0.57 |
| Sharpe Ratio 12m | -0.07 |
| Alpha | -45.29 |
| Beta | 0.064 |
| Volatility | 90.23% |
| Current Volume | 686k |
| Average Volume 20d | 1003.3k |
| Stop Loss | 1.1 (-10.6%) |
| Signal | 0.07 |
Piotroski VR‑10 (Strict, 0-10) 3.0
| Net Income (-18.9m TTM) > 0 and > 6% of Revenue (6% = 11.6m TTM) |
| FCFTA 0.02 (>2.0%) and ΔFCFTA 27.36pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 43.73% (prev 47.74%; Δ -4.01pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.03 (>3.0%) and CFO 5.71m > Net Income -18.9m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 2.00 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (191.3m) change vs 12m ago 3.42% (target <= -2.0% for YES) |
| Gross Margin 56.09% (prev 54.75%; Δ 1.34pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 96.60% (prev 91.64%; Δ 4.96pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -1.17 (EBITDA TTM -8.62m / Interest Expense TTM 8.57m) >= 6 (WARN >= 3) |
Altman Z'' -21.48
| (A) 0.40 = (Total Current Assets 168.5m - Total Current Liabilities 84.4m) / Total Assets 213.1m |
| (B) -5.06 = Retained Earnings (Balance) -1.08b / Total Assets 213.1m |
| warn (B) unusual magnitude: -5.06 — check mapping/units |
| (C) -0.05 = EBIT TTM -10.0m / Avg Total Assets 199.3m |
| (D) -6.88 = Book Value of Equity -1.08b / Total Liabilities 156.9m |
| Total Rating: -21.48 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 39.25
| 1. Piotroski 3.0pt = -2.0 |
| 2. FCF Yield 1.45% = 0.73 |
| 3. FCF Margin 1.78% = 0.44 |
| 4. Debt/Equity 1.58 = 1.37 |
| 5. Debt/Ebitda -10.15 = -2.50 |
| 6. ROIC - WACC -12.23% = -12.50 |
| 7. RoE -34.24% = -2.50 |
| 8. Rev. Trend 65.48% = 3.27 |
| 9. Rev. CAGR 10.79% = 1.35 |
| 10. EPS Trend 63.60% = 1.59 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of CERS shares?
Over the past week, the price has changed by -5.38%, over one month by -3.15%, over three months by -12.77% and over the past year by -40.29%.
Is Cerus a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CERS is around 0.79 USD . This means that CERS is currently overvalued and has a potential downside of -35.77%.
Is CERS a buy, sell or hold?
- Strong Buy: 4
- Buy: 0
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the CERS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 4.7 | 279.7% |
| Analysts Target Price | 4.7 | 279.7% |
| ValueRay Target Price | 0.9 | -30.1% |
Last update: 2025-09-12 04:33
CERS Fundamental Data Overview
CCE Cash And Equivalents = 78.0m USD (Cash And Short Term Investments, last quarter)
P/S = 1.175
P/B = 4.0811
Beta = 1.634
Revenue TTM = 192.5m USD
EBIT TTM = -10.0m USD
EBITDA TTM = -8.62m USD
Long Term Debt = 56.8m USD (from longTermDebt, last quarter)
Short Term Debt = 30.7m USD (from shortTermDebt, last quarter)
Debt = 87.5m USD (Calculated: Short Term 30.7m + Long Term 56.8m)
Net Debt = 82.9m USD (from netDebt column, last quarter)
Enterprise Value = 235.7m USD (226.2m + Debt 87.5m - CCE 78.0m)
Interest Coverage Ratio = -1.17 (Ebit TTM -10.0m / Interest Expense TTM 8.57m)
FCF Yield = 1.45% (FCF TTM 3.42m / Enterprise Value 235.7m)
FCF Margin = 1.78% (FCF TTM 3.42m / Revenue TTM 192.5m)
Net Margin = -9.81% (Net Income TTM -18.9m / Revenue TTM 192.5m)
Gross Margin = 56.09% ((Revenue TTM 192.5m - Cost of Revenue TTM 84.5m) / Revenue TTM)
Tobins Q-Ratio = -0.22 (set to none) (Enterprise Value 235.7m / Book Value Of Equity -1.08b)
Interest Expense / Debt = 2.46% (Interest Expense 2.15m / Debt 87.5m)
Taxrate = 21.0% (US default)
NOPAT = -10.0m (EBIT -10.0m, no tax applied on loss)
Current Ratio = 2.00 (Total Current Assets 168.5m / Total Current Liabilities 84.4m)
Debt / Equity = 1.58 (Debt 87.5m / last Quarter total Stockholder Equity 55.4m)
Debt / EBITDA = -10.15 (Net Debt 82.9m / EBITDA -8.62m)
Debt / FCF = 25.56 (Debt 87.5m / FCF TTM 3.42m)
Total Stockholder Equity = 55.1m (last 4 quarters mean)
RoA = -8.86% (Net Income -18.9m, Total Assets 213.1m )
RoE = -34.24% (Net Income TTM -18.9m / Total Stockholder Equity 55.1m)
RoCE = -8.95% (Ebit -10.0m / (Equity 55.1m + L.T.Debt 56.8m))
RoIC = -7.18% (NOPAT -10.0m / Invested Capital 139.5m)
WACC = 5.05% (E(226.2m)/V(313.7m) * Re(6.25%)) + (D(87.5m)/V(313.7m) * Rd(2.46%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 93.94 | Cagr: 0.70%
Discount Rate = 6.25% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 73.44% ; FCFE base≈3.42m ; Y1≈2.58m ; Y5≈1.56m
Fair Price DCF = 0.15 (DCF Value 29.4m / Shares Outstanding 191.7m; 5y FCF grow -29.09% → 3.0% )
Revenue Correlation: 65.48 | Revenue CAGR: 10.79%
Rev Growth-of-Growth: 4.40
EPS Correlation: 63.60 | EPS CAGR: 0.0%
EPS Growth-of-Growth: -53.08
Additional Sources for CERS Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle